Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesAug 4, 2005View HTMLDownload DOCDownload PDF
424B3Form of prospectus reflecting facts events constituting substantive change from last formAug 3, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventAug 2, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventAug 2, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJul 19, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJul 15, 2005View HTMLDownload DOCDownload PDFDownload XLS
424B5Form of prospectus disclosing information facts events covered in both forms 424B2 424B3Jul 15, 2005View HTMLDownload DOCDownload PDFDownload XLS
UPLOADCorrespondence from the SEC to the FilerJul 14, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 14, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 14, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 14, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 11, 2005View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 11, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 6, 2005View HTMLDownload DOCDownload PDF
3Initial filing by director officer or owner of more than ten percent.Jul 6, 2005View HTMLDownload DOCDownload PDF
8-K/AAmendment to a previously filed 8-KJul 6, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-K/AAmendment to a previously filed 8-KJul 6, 2005View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.Jul 6, 2005View HTMLDownload DOCDownload PDF
3Initial filing by director officer or owner of more than ten percent.Jul 6, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJul 5, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJul 5, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 30, 2005View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GJun 27, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJun 23, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 16, 2005View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-107

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information